RAC-1-(3-(ALLYLOXY)-2-(2,4-DICHLOROPHENYL)PROPYL)-1H-1,2,4-TRIAZOLE


Source	Gaulton A, Kale N, van Westen GJ, Bellis LJ, Bento AP, Davies M, Hersey A, Papadatos G, Forster M, Wege P, Overington JP. A large-scale crop protection bioassay data set. Sci Data. 2015 Jul 7;2:150032. Read more ...


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	OHILTJIKJPVBGV-UHFFFAOYSA-N
Smiles	Clc1ccc(C(COCC=C)Cn2cncn2)c(Cl)c1
InChI	InChI=1S/C14H15Cl2N3O/c1-2-5-20-8-11(7-19-10-17-9-18-19)13-4-3-12(15)6-14(13)16/h2-4,6,9-11H,1,5,7-8H2

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C14H15Cl2N3O
Molecular Weight	312.19
AlogP	3.15
Hydrogen Bond Acceptor	3.0
Hydrogen Bond Donor	0.0
Number of Rotational Bond	7.0
Polar Surface Area	39.94
Molecular species	NEUTRAL
Aromatic Rings	2.0
Heavy Atoms	20.0

Assay Description	Organism	Bioactivity
Inhibition of 14alpha-demethylase Ustilago maydis ATCC 14826 assessed as reduction in 14alpha-methylfecosterol	Ustilago maydis	0.54 ug.mL-1
Inhibition of 14alpha-demethylase Ustilago maydis ATCC 14826 assessed as reduction in 14alpha-methylfecosterol at 20 mg/ml (Rvb = 0.4%)	Ustilago maydis	8.8 %
Inhibition of 14alpha-demethylase Ustilago maydis ATCC 14826 assessed as reduction in ergosterol at 20 mg/ml (Rvb = 61%)	Ustilago maydis	5.1 %
Inhibition of 14alpha-demethylase Ustilago maydis ATCC 14826 assessed as reduction in obtusifoliol at 20 mg/ml (Rvb = 0.7%)	Ustilago maydis	20.6 %
Inhibition of 14alpha-demethylase Ustilago maydis ATCC 14826 assessed as reduction in eburicol at 20 mg/ml (Rvb = 3.4%)	Ustilago maydis	61.1 %
Fungicidal activity against Podosphaera fuliginea inoculated in Phaseolus vulgaris placed in growth room after 24 hr incubation assessed as direct protection after 6 to 10 days	Podosphaera fuliginea	30.0 ug.mL-1
Fungicidal activity against Uromyces appendiculatus inoculated in Phaseolus vulgaris placed in growth room after 24 hr incubation assessed as disease cure after 24 hr of inoculation	Uromyces appendiculatus	28.0 ug.mL-1
Fungicidal activity against Uromyces appendiculatus inoculated in Phaseolus vulgaris placed in growth room after 24 hr incubation assessed as direct protection after 6 to 10 days	Uromyces appendiculatus	200.0 ug.mL-1
Antifungal activity against Ustilago maydis assessed as inhibition of radial growth on potato dextrose	Ustilago maydis	0.22 ug.mL-1
Antifungal activity against Pyrenophora teres assessed as inhibition of radial growth on potato dextrose	Pyrenophora teres	1.4 ug.mL-1
Antifungal activity against Cochliobolus heterostrophus assessed as inhibition of radial growth on potato dextrose	Cochliobolus heterostrophus	0.16 ug.mL-1
Antifungal activity against Oculimacula yallundae assessed as inhibition of radial growth on potato dextrose	Oculimacula yallundae	0.29 ug.mL-1
Antifungal activity against Fusarium graminearum assessed as inhibition of radial growth on potato dextrose	Fusarium graminearum	8.5 ug.mL-1
Antifungal activity against Cercospora beticola assessed as inhibition of radial growth on potato dextrose	Cercospora beticola	0.21 ug.mL-1
Antifungal activity against Botryotinia fuckelianaassessed as inhibition of radial growth on potato dextrose	Botryotinia fuckeliana	1.5 ug.mL-1

Cross References

Resources	Reference
ChEMBL	CHEMBL2269563
PubChem	15096531

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).